Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., June 05, ...

Casma Therapeutics Inc. has nominated its first development candidate, CSM-101, a first-in-class TRPML1 agonist. CSM-101 is being developed for the treatment of Gaucher’s disease patients with ...

Lysosomal homeostasis is crucial to the metabolism of certain proteins and lipids that would otherwise accumulate, thus leading to cellular stress and pathology. This is common in diseases such as ...

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced the nomination of its first development candidate, ...

Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease Casma’s first-in-class TRPML1 agonist represents a new therapeutic ...